+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Generic Oncology Drugs Market by Molecule, by Administration Route, and by Distribution Channel: Global Market Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025

  • ID: 4854557
  • Report
  • July 2019
  • Region: Global
  • 120 pages
  • Zion Market Research
1 of 2

The report covers a forecast and an analysis of the global generic oncology drugs market on a global and regional level. The study provides historical data for 2017 and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes the drivers and restraints of the global generic oncology drugs market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the global generic oncology drugs market on a global level.

In order to give the users of this report a comprehensive view of the global generic oncology drugs market. We have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the global generic oncology drugs market is segmented on the basis of molecule, administration route, distribution channel, and region. The regional segment includes North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa.

Some major companies in the global generic oncology drugs market are Amgen, Bayer Healthcare, Teva Pharmaceutical, Boehringer Ingelheim, Pfizer, AstraZeneca, Eli Lily and Company, Hoffmann-La Roche, ARIAD Pharmaceuticals, CELGENE Corporation, GlaxoSmithKline, Novartis, Johnson and Johnson, Merck, AbbVie, and Sanofi.

This report segments the global generic oncology drugs market into:

Global Generic Oncology Drugs Market: Molecule Analysis

  • Large Molecule
  • Small Molecule

Global Generic Oncology Drugs Market: Administration Route Analysis

  • Oral
  • Parenteral

Global Generic Oncology Drugs Market: Distribution Channel Analysis

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Generic Oncology Drugs Market: Regional Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Generic Oncology Drugs market, 2017-2025 (USD Million)
    • 2.2. Global Generic Oncology Drugs Market: Snapshot
  • Chapter 3. Global Generic Oncology Drugs Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Cancer Incidences
      • 3.2.2. Growing R&D Spending
      • 3.2.3. Favorable Reimbursement Scenario in Developed Countries
      • 3.2.4. Increasing demand for Generic Oncology Drugs
    • 3.3. Market Restraints
      • 3.3.1. Side Effects of Cancer Drugs
      • 3.3.2. Low Affordability in Developing Countries
      • 3.3.3. Low Awareness about Generic Oncology Drugs
    • 3.4. Opportunities
      • 3.4.1. Strategic Alliances formed by Generic Oncology Drugs Companies
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by Molecule
      • 3.6.2. Market attractiveness analysis, by Administration Route
      • 3.6.3. Market attractiveness analysis, by Distribution Channel
      • 3.6.4. Market attractiveness analysis, by region
  • Chapter 4. Global Generic Oncology Drugs Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Generic Oncology Drugs Market: Company Market Share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Generic Oncology Drugs Market - Molecule analysis
    • 5.1. Global Generic Oncology Drugs Market: Molecule overview
      • 5.1.1. Global Generic Oncology Drugs Market Revenue Share, by Molecule, 2018 and 2025
    • 5.2. Large Molecule
      • 5.2.1. Global Generic Oncology Drugs Market for Large Molecule, 2017-2025 (USD Million)
    • 5.3. Small Molecule
      • 5.3.1. Global Generic Oncology Drugs Market for Small Molecule, 2017-2025 (USD Million)
  • Chapter 6. Global Generic Oncology Drugs Market - Administration Route Analysis
    • 6.1. Global Generic Oncology Drugs Market: Administration Route
      • 6.1.1. Global Generic Oncology Drugs Market Revenue Share, by Administration Route, 2018 and 2025
    • 6.2. Oral
      • 6.2.1. Global Generic Oncology Drugs Market for Oral, 2017-2025 (USD Million)
    • 6.3. Parenteral
      • 6.3.1. Global Generic Oncology Drugs Market for Parenteral, 2017-2025 (USD Million)
  • Chapter 7. Global Generic Oncology Drugs Market - Distribution Channel Analysis
    • 7.1. Global Generic Oncology Drugs Market Distribution Channel
      • 7.1.1. Global Generic Oncology Drugs Market Revenue Share, by Distribution Channel, 2018 and 2025
    • 7.2. Hospital Pharmacy
      • 7.2.1. Global Generic Oncology Drugs Market for Hospital Pharmacy, 2017-2025 (USD Million)
    • 7.3. Retail Pharmacy
      • 7.3.1. Global Generic Oncology Drugs Market for Retail Pharmacy, 2017-2025 (USD Million)
    • 7.4. Online Pharmacy
      • 7.4.1. Global Generic Oncology Drugs Market for Online Pharmacy, 2017-2025 (USD Million)
  • Chapter 8. Global Generic Oncology Drugs Market - Regional Analysis
    • 8.1. Global Generic Oncology Drugs Market: Regional Overview
      • 8.1.1. Global Generic Oncology Drugs Market Revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.2.2. North America Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.2.3. North America Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.2.4.2. The U.S. Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.2.4.3. The U.S. Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.2.5.2. Rest of North America Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.2.5.3. Rest of North America Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.3.2. Europe Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.3.3. Europe Generic Oncology Drugs Market Revenue, by End -User, 2017-2025 (USD Million)
      • 8.3.4. UK
        • 8.3.4.1. UK Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.3.4.2. UK Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.3.4.3. UK Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.3.5.2. Germany Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.3.5.3. Germany Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.3.6.2. France Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.3.6.3. France Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.3.7.2. Rest of Europe Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.3.7.3. Rest of Europe Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.4.2. Asia Pacific Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.4.3. Asia Pacific Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.4.4.2. China Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.4.4.3. China Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.4.5.2. Japan Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.4.5.3. Japan Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.4.6.2. India Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.4.6.3. India Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.4.7.2. Rest of Asia Pacific Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.4.7.3. Rest of Asia Pacific Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.5.2. Latin America Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.5.3. Latin America Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.5.4.2. Brazil Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.5.4.3. Brazil Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.5.5.2. Rest of Latin America Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.5.5.3. Rest of Latin America Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
  • Chapter 9. Company Profile
    • 9.1. Amgen
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Molecule portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Bayer Healthcare
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Molecule portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Teva Pharmaceutical Industries
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Molecule portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Boehringer Ingelheim
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Molecule portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Pfizer
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Molecule portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. AstraZeneca
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Molecule portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Eli Lily and Company
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Molecule portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Hoffmann-La Roche
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Molecule portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. ARIAD Pharmaceuticals
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Molecule portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. CELGENE Corporation
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Molecule portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. GlaxoSmithKline
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Molecule portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments
    • 9.12. Novartis
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Molecule portfolio
      • 9.12.4. Business strategy
      • 9.12.5. Recent developments
    • 9.13. Johnson and Johnson
      • 9.13.1. Overview
      • 9.13.2. Financials
      • 9.13.3. Molecule portfolio
      • 9.13.4. Business strategy
      • 9.13.5. Recent developments
    • 9.14. Merck
      • 9.14.1. Overview
      • 9.14.2. Financials
      • 9.14.3. Molecule portfolio
      • 9.14.4. Business strategy
      • 9.14.5. Recent developments
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll